Related Experiment Video
Updated: Jul 30, 2026
Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
Evaluation of the serologic response against two consensus V3 loop peptides from human immunodeficiency virus-1 in
Insights
Cuban patients with human immunodeficiency virus (HIV) showed high antibody reactivity to V3 loop peptides of glycoprotein gp120. Antibody levels did not predict disease progression, but these peptides show promise for HIV vaccines.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Human immunodeficiency virus (HIV) infection is a global health challenge.
- The V3 loop of the HIV-1 gp120 envelope protein is a key target for neutralizing antibodies.
- Understanding antibody responses to V3 loop peptides is crucial for vaccine development.
Purpose of the Study:
- To evaluate the antibody response in Cuban patients infected with HIV-1 against two consensus V3 loop peptides of gp120.
- To assess the correlation between antibody titers, avidity indexes, and disease progression.
- To explore the potential of these peptides in experimental HIV vaccines.
Main Methods:
- A retrospective study involving sera from 10 HIV-1 infected individuals.
- Indirect enzyme-linked immunoassay used to determine antibody titers and avidity indexes.
- Two synthetic 15-meric peptides from consensus sequences of HIV-1 groups B and C were employed.
Main Results:
- High reactivity (80%) was observed against at least one of the V3 loop peptides.
- Antibody titers and avidity indexes did not correlate with HIV disease progression.
- One patient exhibited higher avidity against a homologous peptide, suggesting potential for specific responses.
Conclusions:
- Consensus V3 loop peptides elicit strong antibody responses in HIV-infected individuals.
- Further large-scale studies are needed to determine if anti-V3 antibody levels predict disease progression.
- The studied peptides are potential candidates for inclusion in future HIV vaccine formulations.
Objectives:
A retrospective study was conducted to evaluate the antibody response of Cuban patients infected with human immunodeficiency virus (HIV)-1 against two consensus peptides from the third variable domain (V3) loop of glycoprotein gp120.
Methods:
The study included sera from 10 individuals at different stages of disease. Two 15-meric synthetic peptides designed from a consensus sequence, belonging to group B or C of HIV-1, were used to determine antibody titers and avidity indexes in an indirect enzyme-linked immunoassay.
Results:
A high reactivity against both peptides was detected, with 80% of the sera reacting with at least one of the peptides. The antibody titers and avidity indexes did not correlate with disease progression. Additionally, for one of the patients from whom the virus had been isolated, a higher avidity index was found against the homologous peptide.
Conclusions:
This study showed high reactivity against two consensus peptides from the V3 loop of gp120 among patients with HIV. Large scale studies are needed to determine whether the titers or avidity of anti-V3 antibodies, at the early stages of infection, are predictive of disease progression. Both peptides are candidates for inclusion in experimental vaccines.
